Save
Combined triaxial accelerometeric sensors and ultrasonography-guided botulinum toxin type-A injection can improve outcome in upper extremities tremor in multiple sclerosis
Author(s): ,
H. Shehata
Affiliations:
Neurology Department
,
N. Shalaby
Affiliations:
Neurology Department
,
M. Basheer
Affiliations:
Neurophysiology Department, Cairo University, Cairo, Egypt
M. Abdel-Naseer
Affiliations:
Neurology Department
ECTRIMS Online Library. Shehata H. Oct 12, 2018; 228161
Hatem Shehata
Hatem Shehata
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Discussion Forum (0)
Rate & Comment (0)

Abstract: P1783

Type: Poster Sessions

Abstract Category: N/A

Background: Focal treatment of upper extremities (UE) tremor by onabotulinumtoxin-A (BoNT-A) injections in multiple sclerosis (MS) has been inadequately investigated. Though few reports showed modest effects; yet, absence of large scale studies, heterogeneous tremor presentation and diverse regimens to target a multi-joint tremulous movement make it difficult to reach an objective consensus regarding its value.
Objective: This was a 24-week open-label study to assess the role of BoNT-A injections in disabling MS-related upper limb tremor.
Methods: Participants (n=34) with resistant to treat UE tremors attended study visits at weeks 0, 2, 4, 12, 16, 20 and 24 (data-lock visit). During each visit patients were subjected to standardized videotaping (during rest, posture and motion), tremor assessment using Fahn-Tolosa-Marin (FTM) tremor motor scale and Archimedes spiral drawings. BoNT-A injection was determined using surface EMG (tremor frequency) and ultrasonography of muscles that may contribute to the tremor across a variety of joints in all degrees of movement using tri-axial accelerometeric sensors to measure UE kinematics and in which axes of the sensors were aligned with the main joint axes. Re-injection was done whenever needed at weeks 16 or 20.
Resuls: A significant decrease in FTM tremor severity score and Archimedes spiral drawing at week 4 (p< 0.01, P=0.002 respectively) and at week 12 (P=0.03, P=0.06 respectively). Re-injection was done for 7 patients with continuous satisfactory response. Muscle weakness was detected in 3/34 patients with limb tremor, which was mild and transient (resolved within 2 weeks).
Conclusion: BoNT-A could be a promising option for improving resistant to treat UE tremor in MS using a multi technical approach for directional assessment of tremor at each arm joint.
Disclosure: nothing to disclose

Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings